The National Institute for Health and Care Excellence has now published its new guidance and cost effectiveness appraisal on the use of bisphosphonates for preventing bone fractures in people at increased risk. The new guidance links a person’s risk of having a bone fracture with the point at which treatment should be started, based on cost effectiveness – this is called a multi technology appraisal.
It recommends treatment with the bisphosphonate drugs alendronic acid, ibandronic acid and risedronate sodium as options for people who have at least a 1% risk of a bone fracture within the next 10 years.…
Read more of this article